Swedish Orphan Biovitrum AB (publ) (SOBI) - Total Liabilities
Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) has total liabilities worth Skr29.71 Billion SEK as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Swedish Orphan Biovitrum AB (publ) - Total Liabilities Trend (2002–2025)
This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Swedish Orphan Biovitrum AB (publ) Competitors by Total Liabilities
The table below lists competitors of Swedish Orphan Biovitrum AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nordson Corporation
NASDAQ:NDSN
|
USA | $2.87 Billion |
|
AB Volvo (publ)
ST:VOLV-A
|
Sweden | Skr470.11 Billion |
|
Banco de Credito e Inversiones
SN:BCI
|
Chile | CL$74.12 Trillion |
|
Bank of Baroda
NSE:BANKBARODA
|
India | Rs18.06 Trillion |
|
W P Carey Inc
NYSE:WPC
|
USA | $9.86 Billion |
|
Shenwan Hongyuan Group Co Ltd
SHE:000166
|
China | CN¥582.43 Billion |
|
Sands China Ltd
F:599A
|
Germany | €9.17 Billion |
|
Banco de Sabadell S.A
MC:SAB
|
Spain | €231.31 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Swedish Orphan Biovitrum AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.06 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Swedish Orphan Biovitrum AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Swedish Orphan Biovitrum AB (publ) (2002–2025)
The table below shows the annual total liabilities of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr29.71 Billion | -15.47% |
| 2024-12-31 | Skr35.15 Billion | -12.48% |
| 2023-12-31 | Skr40.16 Billion | +54.63% |
| 2022-12-31 | Skr25.97 Billion | +2.02% |
| 2021-12-31 | Skr25.46 Billion | -9.33% |
| 2020-12-31 | Skr28.08 Billion | -2.27% |
| 2019-12-31 | Skr28.73 Billion | +252.79% |
| 2018-12-31 | Skr8.14 Billion | +93.77% |
| 2017-12-31 | Skr4.20 Billion | -9.04% |
| 2016-12-31 | Skr4.62 Billion | +27.57% |
| 2015-12-31 | Skr3.62 Billion | +95.98% |
| 2014-12-31 | Skr1.85 Billion | +5.59% |
| 2013-12-31 | Skr1.75 Billion | +18.21% |
| 2012-12-31 | Skr1.48 Billion | -14.73% |
| 2011-12-31 | Skr1.74 Billion | -36.34% |
| 2010-12-31 | Skr2.73 Billion | +87.73% |
| 2009-12-31 | Skr1.45 Billion | +12.28% |
| 2008-12-31 | Skr1.29 Billion | +161.12% |
| 2007-12-31 | Skr495.50 Million | -28.79% |
| 2006-12-31 | Skr695.87 Million | -31.81% |
| 2005-12-31 | Skr1.02 Billion | +196.35% |
| 2004-12-31 | Skr344.34 Million | +23.90% |
| 2003-12-31 | Skr277.92 Million | +4.25% |
| 2002-12-31 | Skr266.58 Million | -- |
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more